Please assess the completion status of the following clinical trial:

Trial Title: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe stable chronic plaque psoriasis for at least 6 months, with or without psoriatic arthritis~* Affected body surface area (BSA) greater than or equal to 15%~* Physician's Global Assessment (PGA) score of 3 or more~* Female subjects of non-childbearing potential or postmenopausal for at least 1 year. Male subjects must agree to use effective method of birth control~* Body Mass Index (BMI) less than or equal to 38.0 kg/m2~Exclusion Criteria:~* Concomitant anti-psoriatic treatment~* Infectious disease requiring systemic anti-infectious treatment within the 2 weeks prior to administration of trial drug~* Known history of Human Immunodeficiency Virus (HIV)~* Hepatitis B and/or C (determined by test)~* Live virus or bacteria vaccines within the last month before drug administration~* Known active herpes/herpes zoster/cold sores~* Kidney insufficiency~* Liver insufficiency~* Lymphoproliferative disease~* History or signs of malignancy within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Anti-IL-20 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).